Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Division of Dermatology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada.
Dermatol Ther. 2020 Nov;33(6):e14261. doi: 10.1111/dth.14261. Epub 2020 Sep 27.
Apremilast is an orally administered small molecule that specifically inhibits the phosphodiesterase-4 enzyme and modulates the immune system by increasing the levels of intracellular cyclic adenosine monophosphate (cAMP) and inhibiting IL-2 & 8, interferon-γ and tumor necrosis factor (TNF) production. It is FDA approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers of Behcet's disease. More recently, apremilast has been used off-label to treat varied dermatological diseases where systemic corticosteroids or immunosuppressive agents were not effective. We review the efficacy and safety of apremilast in the treatment of aphthous stomatitis, Behçet's disease, chronic actinic dermatitis, atopic dermatitis, cutaneous sarcoidosis, hidradenitis suppurativa, lichen planus, and discoid lupus erythematosus in cases where standard treatment has failed.
阿普斯特是一种口服小分子药物，特异性抑制磷酸二酯酶-4 酶，并通过增加细胞内环腺苷酸（cAMP）的水平和抑制白细胞介素-2 和 8、干扰素-γ和肿瘤坏死因子（TNF）的产生来调节免疫系统。它已被 FDA 批准用于治疗银屑病、银屑病关节炎和白塞病的口腔溃疡。最近，阿普斯特已被用于治疗在使用全身皮质类固醇或免疫抑制剂治疗无效的各种皮肤科疾病。我们回顾了阿普斯特在治疗复发性阿弗他口炎、白塞病、慢性光化性皮炎、特应性皮炎、皮肤结节病、化脓性汗腺炎、扁平苔藓和盘状红斑狼疮中的疗效和安全性，这些疾病在标准治疗失败的情况下。
